Health
Commonly-prescribed drug for IBD blunts COVID-19 vaccine response – News-Medical.Net
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after…
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.
The research measured antibody responses after vaccination with the Pfizer/BioNTech or the Oxford/AstraZeneca COVID-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide. Anti-TNF…
-
Noosa News23 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business21 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News19 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Noosa News21 hours ago150 jobs in doubt as Bega winds down peanut processing plants in Queensland